July 28: At ADLM 2026, Randox will showcase its Acusera Serum Indices Control, highlighting how independent HIL (Hemolysis, Icterus, and Lipemia) quality control helps laboratories verify analyzer performance before patient samples are analyzed. Visitors to the Randox booth will have the opportunity to attend expert-led workshops and educational sessions, exploring best practices for HIL detection and strengthening confidence in pre-analytical quality.
Pre-analytical errors caused by hemolysis, icterus, and lipemia remain among the leading causes of rejected specimens, repeat testing, and inaccurate clinical results. Ensuring analyzers can consistently detect these common sample interferences is essential for maintaining analytical quality and protecting patient safety. Independent HIL quality control enables laboratories to routinely verify analyzer performance, providing confidence that interfering samples are identified before quantitative analysis begins.
Designed specifically to assess an analyzer’s ability to detect hemolyzed, icteric, and lipemic samples, the Acusera Serum Indices Control provides a comprehensive range of clinically relevant challenge levels. Each control pack includes one negative (-) and three positive (+, ++, and +++) levels for all three interferents, enabling laboratories to verify performance across the full analytical range while reducing the need to purchase and manage multiple individual control products.
Throughout ADLM 2026, Randox specialists will be available to discuss the growing importance of HIL quality control, explain how independent verification supports laboratory quality assurance, and highlight how the Acusera Serum Indices Control can help laboratories strengthen confidence in every patient result from the earliest stage of the testing process.